Related Experiment Video

Updated: Sep 1, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

897

The prognostic role of galectin-3 and endothelial function in patients with heart failure

Vasiliki Tsigkou1,2, Gerasimos Siasos1,2,3, Evangelos Oikonomou4,5

  • 1Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Cardiology Journal
|August 17, 2022
PubMed

Insights

Flow-mediated dilatation improved with left ventricular ejection fraction in ischemic heart failure patients. Worse FMD and higher galectin-3 levels are linked to major adverse cardiovascular events, aiding risk stratification.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Biomarkers

Background:

  • Heart failure (HF) is classified into HFrEF, HFmrEF, and HFpEF.
  • Endothelial dysfunction (FMD), arterial stiffness (PWV), and galectin-3 are linked to MACE in ischemic HF.
  • Understanding these markers' relationship with HF subtypes and outcomes is crucial.

Purpose of the Study:

  • To investigate the association between FMD, PWV, galectin-3, and LVEF in ischemic HF patients.
  • To determine the predictive value of these markers for MACE.
  • To explore their role in stratifying risk across different HF classifications.

Main Methods:

  • Prospective enrollment of 340 stable ischemic HF patients.
  • Assessment of brachial artery FMD, carotid-femoral PWV, and serum galectin-3 levels.
  • Follow-up for MACE, analyzed by HF group and marker levels.

Main Results:

  • FMD showed a stepwise improvement with increasing LVEF (HFpEF > HFmrEF > HFrEF), significant after confounder adjustment.
  • PWV was not associated with LVEF.
  • Worse FMD values and higher galectin-3 tertiles were significantly associated with increased MACE.

Conclusions:

  • Flow-mediated dilatation demonstrates a linear improvement with LVEF in ischemic HF.
  • Deteriorated FMD and elevated galectin-3 are associated with MACE, suggesting their utility in risk stratification.
  • Galectin-3 may aid in identifying high-risk ischemic HF patients.
Abstract

Keywords:
ejection fractionendothelial functiongalectin-3heart failureprognosis

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

15.9K

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
39
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
132
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
40